Seegene (A096530) Stock Overview
Manufactures and sells molecular diagnostics products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
A096530 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Seegene, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩23,900.00 |
| 52 Week High | ₩36,650.00 |
| 52 Week Low | ₩21,700.00 |
| Beta | 0.80 |
| 1 Month Change | 7.90% |
| 3 Month Change | -0.42% |
| 1 Year Change | 1.49% |
| 3 Year Change | -11.15% |
| 5 Year Change | -75.98% |
| Change since IPO | 468.15% |
Recent News & Updates
Recent updates
Seegene's (KOSDAQ:096530) Performance Is Even Better Than Its Earnings Suggest
Mar 27
Seegene (KOSDAQ:096530) Seems To Use Debt Rather Sparingly
Nov 25Does Seegene (KOSDAQ:096530) Have A Healthy Balance Sheet?
Jul 24Seegene, Inc. (KOSDAQ:096530) Shares Fly 25% But Investors Aren't Buying For Growth
May 13Seegene, Inc. (KOSDAQ:096530) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Jan 08Investors Shouldn't Be Too Comfortable With Seegene's (KOSDAQ:096530) Earnings
Nov 22Is Seegene (KOSDAQ:096530) Using Too Much Debt?
Nov 12Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too
Aug 10A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)
Mar 07Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?
May 06I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease
Mar 15Does Seegene (KOSDAQ:096530) Have A Healthy Balance Sheet?
Feb 25Shareholder Returns
| A096530 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 6.9% | 1.4% | 8.3% |
| 1Y | 1.5% | 35.2% | 130.0% |
Return vs Industry: A096530 underperformed the KR Biotechs industry which returned 36.5% over the past year.
Return vs Market: A096530 underperformed the KR Market which returned 126.6% over the past year.
Price Volatility
| A096530 volatility | |
|---|---|
| A096530 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A096530 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A096530's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Jong-Yoon Chun | www.seegene.com |
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes.
Seegene, Inc. Fundamentals Summary
| A096530 fundamental statistics | |
|---|---|
| Market cap | ₩1.10t |
| Earnings (TTM) | ₩48.27b |
| Revenue (TTM) | ₩474.23b |
Is A096530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A096530 income statement (TTM) | |
|---|---|
| Revenue | ₩474.23b |
| Cost of Revenue | ₩170.37b |
| Gross Profit | ₩303.86b |
| Other Expenses | ₩255.59b |
| Earnings | ₩48.27b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.05k |
| Gross Margin | 64.08% |
| Net Profit Margin | 10.18% |
| Debt/Equity Ratio | 7.5% |
How did A096530 perform over the long term?
See historical performance and comparisonDividends
Does A096530 pay a reliable dividends?
See A096530 dividend history and benchmarks| Seegene dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Apr 10 2026 |
| Days until Ex dividend | 104 days |
| Days until Dividend pay date | 2 days |
Does A096530 pay a reliable dividends?
See A096530 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 14:30 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Seegene, Inc. is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Lee | CLSA |
| Jonghyun Park | DAOL Investment & Securities Co., Ltd. |
| Jinhee Kwak | Eugene Investment & Securities Co Ltd. |